The Worst of 2012: Halozyme Therapeutics
It's the end of 2012, and that means it's time to take a look back at the year in retrospect. We'll be reading through the naughty and nice list (we've already checked it twice), counting down the 25 best-performing stocks and the 25 worst-performing stocks in the health care sector this year.
In this segment, Motley Fool health care analysts Brenton Flynn and Max Macaluso take a look at No. 24 on the naughty list: Halozyme Therapeutics (NAS: HALO) and why this company deserves coal in its stocking.
While looking at 2012 performance is useful, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article The Worst of 2012: Halozyme Therapeutics originally appeared on Fool.com.Brenton Flynn, Max Macaluso, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.